WO2013030577A1 - Method for detecting nucleosomes containing nucleotides - Google Patents
Method for detecting nucleosomes containing nucleotides Download PDFInfo
- Publication number
- WO2013030577A1 WO2013030577A1 PCT/GB2012/052128 GB2012052128W WO2013030577A1 WO 2013030577 A1 WO2013030577 A1 WO 2013030577A1 GB 2012052128 W GB2012052128 W GB 2012052128W WO 2013030577 A1 WO2013030577 A1 WO 2013030577A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide
- nucleosomes
- nucleosome
- nucleoside
- dna base
- Prior art date
Links
- 108010047956 Nucleosomes Proteins 0.000 title claims abstract description 413
- 210000001623 nucleosome Anatomy 0.000 title claims abstract description 412
- 238000000034 method Methods 0.000 title claims abstract description 205
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 204
- 239000002773 nucleotide Substances 0.000 title claims abstract description 202
- 239000000090 biomarker Substances 0.000 claims abstract description 111
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 98
- 201000010099 disease Diseases 0.000 claims abstract description 77
- 238000001514 detection method Methods 0.000 claims abstract description 76
- 238000005259 measurement Methods 0.000 claims abstract description 34
- 238000003745 diagnosis Methods 0.000 claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 118
- 210000004027 cell Anatomy 0.000 claims description 102
- 201000011510 cancer Diseases 0.000 claims description 96
- 239000002585 base Substances 0.000 claims description 82
- 210000002381 plasma Anatomy 0.000 claims description 80
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 63
- 210000002966 serum Anatomy 0.000 claims description 63
- 239000002777 nucleoside Substances 0.000 claims description 60
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 60
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 claims description 47
- 239000011230 binding agent Substances 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 210000001124 body fluid Anatomy 0.000 claims description 30
- 239000010839 body fluid Substances 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 28
- 238000012544 monitoring process Methods 0.000 claims description 26
- 239000003446 ligand Substances 0.000 claims description 23
- 108010077544 Chromatin Proteins 0.000 claims description 21
- 210000003483 chromatin Anatomy 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 17
- 208000029742 colonic neoplasm Diseases 0.000 claims description 15
- 210000004072 lung Anatomy 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 13
- 210000000496 pancreas Anatomy 0.000 claims description 9
- 239000013060 biological fluid Substances 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 230000003278 mimic effect Effects 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 210000000214 mouth Anatomy 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 229940104302 cytosine Drugs 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 4
- 239000000306 component Substances 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 124
- 108010033040 Histones Proteins 0.000 description 89
- 239000000523 sample Substances 0.000 description 86
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 39
- 238000003018 immunoassay Methods 0.000 description 31
- 238000003556 assay Methods 0.000 description 26
- 230000007067 DNA methylation Effects 0.000 description 24
- 102000006947 Histones Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000012491 analyte Substances 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 239000012472 biological sample Substances 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 208000003445 Mouth Neoplasms Diseases 0.000 description 12
- 210000003040 circulating cell Anatomy 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 201000005202 lung cancer Diseases 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 230000011987 methylation Effects 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 102100023919 Histone H2A.Z Human genes 0.000 description 10
- 101000905054 Homo sapiens Histone H2A.Z Proteins 0.000 description 10
- 230000002583 anti-histone Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Nonanedioid acid Natural products OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 102100039869 Histone H2B type F-S Human genes 0.000 description 8
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 8
- 238000013019 agitation Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 230000004481 post-translational protein modification Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 238000003748 differential diagnosis Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 102100030670 Core histone macro-H2A.2 Human genes 0.000 description 5
- 101710185000 Core histone macro-H2A.2 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
- 238000013198 immunometric assay Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 108091029430 CpG site Proteins 0.000 description 3
- 230000006429 DNA hypomethylation Effects 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 238000002967 competitive immunoassay Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102100034528 Core histone macro-H2A.1 Human genes 0.000 description 2
- 101710184999 Core histone macro-H2A.1 Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 108010022894 Euchromatin Proteins 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000220259 Raphanus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 108050002584 Septin 9 Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000003822 cell turnover Effects 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 210000000632 euchromatin Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- 238000007031 hydroxymethylation reaction Methods 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010034959 macroH2A histone Proteins 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
- ZALMSPFXLKMWDY-GMJFWCJPSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(1-hydroxyethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1[C@H](O)[C@@H](C(O)C)O[C@H]1N1C(=O)N=C(N)C=C1 ZALMSPFXLKMWDY-GMJFWCJPSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 101100450031 Caenorhabditis elegans htz-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 108091030081 DNA N(4)-methylcytosine Proteins 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101001084710 Drosophila melanogaster Histone H2A.v Proteins 0.000 description 1
- 102100024739 E3 ubiquitin-protein ligase UHRF1 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100034533 Histone H2AX Human genes 0.000 description 1
- 101710166728 Histone H3 Proteins 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000760417 Homo sapiens E3 ubiquitin-protein ligase UHRF1 Proteins 0.000 description 1
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108020004446 Long Interspersed Nucleotide Elements Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102000012060 Septin 9 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Definitions
- the invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and nucleosomes that contain particular nucleotides and the use of such measurements for the detection and diagnosis of disease.
- the invention also relates to a method of identifying nucleosome associated nucleotide biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.
- the human body comprises several hundred cell types. All of these cell types contain the same genome but have widely different phenotypes and different functions in the body. This phenotypic diversity is due to the differential expression of the genome in different cell types.
- the control of differential gene expression is not entirely understood but the basic mechanisms include gene regulation by a number of interconnected epigenetic signals associated with the gene, including control of the chromatin packing as euchromatin or heterochromatin, control of nucleosome positioning and nuclease accessible sites, methylation, hydroxymethylation and other modifications of DNA and variation in the structure of the nucleosomes around which the DNA is wrapped.
- the nucleosome is the basic unit of chromatin structure and consists of a protein complex of eight highly conserved core histones (comprising a pair of each of the histones H2A, H2B, H3 and H4). Around this complex is wrapped approximately 146 base pairs of DNA. Another histone, H1 or H5, acts as a linker and is involved in chromatin compaction.
- the DNA is wound around consecutive nucleosomes in a structure often said to resemble "beads on a string" and this forms the basic structure of open or euchromatin. In compacted or heterochromatin this string is coiled and super coiled into a closed and complex structure (Herranz and Esteller, 2007).
- the structure of nucleosomes can vary by Post Transcriptional Modification (PTM) of histone proteins and by the inclusion of variant histone proteins.
- PTM of histone proteins typically occurs on the tails of the core histones and common modifications include acetylation, methylation or ubiquitination of lysine residues as well as methylation of arginine residues and phosphorylation of serine residues and many others.
- Histone modifications are known to be involved in epigenetic regulation of gene expression (Herranz and Esteller, 2007).
- the structure of the nucleosome can also vary by the inclusion of alternative histone isoforms or variants which are different gene or splice products and have different amino acid sequences.
- Histone variants can be classed into a number of families which are subdivided into individual types.
- the nucleotide sequences of a large number of histone variants are known and publicly available for example in the National Human Genome Research Institute NHGRI Histone DataBase (Marino-Ramirez, L, Levine, K.M., Morales, M., Zhang, S., Moreland, R.T., Baxevanis, A.D., and Landsman, D.
- the Histone Database an integrated resource for histones and histone fold-containing proteins. Database Vol.201 1.
- GenBank NASH genetic sequence
- EMBL Nucleotide Sequence Database
- DDBJ DNA Data Bank of Japan
- Mononucleosomes and oligonucleosomes can be detected by Enzyme-Linked ImmunoSorbant Assay (ELISA) and several methods have been reported (Salgame et al, 1997; Holdenrieder et al, 2001 ; van Nieuwenhuijze et al, 2003). These assays typically employ an anti-histone antibody (for example anti-H2B, anti-H3 or anti-H1 , H2A, H2B, H3 and H4) as capture antibody and an anti-DNA or anti-H2A-H2B-DNA complex antibody as detection antibody.
- an anti-histone antibody for example anti-H2B, anti-H3 or anti-H1 , H2A, H2B, H3 and H4
- ELISA methods for the detection of histone PTMs are also known in the art. ELISA methods for PTM detection in free histone proteins (not attached to other histones and DNA in a nucleosome complex) are used for the detection of PTMs in histones extracted, usually by acid extraction, from cell lysates. An immunoassay for the detection of PTMs in circulating cell free nucleosomes has been reported (Bawden et al, 2005). A method for ELISA detection of histone PTMs in purified nucleosomes directly coated to microtitre wells has recently been reported (Dai et al, 201 1 ).
- nucleosomes obtained by digestion of chromatin extracts from cultured cells are coated directly to microtitre wells and reacted with anti-PTM antibodies. It will be clear to those skilled in the art that this method requires relatively pure nucleosome samples and is not suitable for the direct measurement of histone PTMs in complex biological media such as blood, plasma or serum.
- a modified chromatin immunoprecipitation (ChIP) method for the detection of a histone PTM (H3K9Me, histone H3 monomethylated at lysine residue K9) in cell free nucleosomes associated with a particular DNA sequence has been reported in plasma.
- Histone variants also known as histone isoforms
- epigenetic regulators of gene expression are known to be epigenetic regulators of gene expression.
- Histone variants have been studied in vivo and in vitro using a variety of techniques including knock-down studies of the gene encoding a particular variant (for example using RNAi knockdown), chromatin immunoprecipitation, stable isotope labeling of amino acids and quantitative mass spectrometry proteomics, immunohistochemistry and Western Blotting (Whittle et al, 2008; Boulard et al, 2010; Sporn et al, 2009; Kapoor ei a/, 2010; Zee et al, 2010; Hua et al, 2008).
- immunohistochemical methods for clinical use is that tissue sample collection is invasive involving surgery or biopsy.
- Another disadvantage of immunohistochemistry methods is that they are unsuited for early diagnosis or for screening diagnostics as a reasonable expectation of the disease must usually already exist before a biopsy or tissue resection is made.
- Minimally invasive blood ELISA tests are suitable for a wider range of applications and would overcome these disadvantages and be preferable for the patient as well as faster, lower cost and more high-throughput for the healthcare provider.
- control of gene expression in cells is also mediated by modifications to DNA nucleotides including the cytosine methylation status of DNA. It has been known in the art for some time that DNA may be methylated at the 5 position of cytosine nucleotides to form 5-methylcytosine. Methylated DNA in the form of 5- methylcytosine is reported to occur at positions in the DNA sequence where a cytosine nucleotide occurs next to a guanine nucleotide. These positions are termed "CpG" for shorthand.
- CpG islands regions of the genome that contain a high proportion of CpG sites are often termed "CpG islands", and approximately 60% of human gene promoter sequences are associated with such CpG islands (Rodriguez-Paredes and Esteller, 201 1 ). In active genes these CpG islands are generally hypomethylated. Methylation of gene promoter sequences is associated with stable gene inactivation. DNA methylation also commonly occurs in repetitive elements including Alu repetitive elements and long interspersed nucleotide elements (Herranz and Estellar, 2007; Allen et al, 2004).
- DNA methylation was reported as early as 1983 (Feinberg and Vogelstein, 1983). DNA methylation patterns observed in cancer cells differ from those of healthy cells. Repetitive elements, particularly around
- pericentromeric areas are reported to be hypomethylated in cancer relative to healthy cells but promoters of specific genes have been reported to be
- Hypermethylation of certain specific genes can be used as a diagnostic biomarker for cancers. For example a method reported for detection of hypermethylation of the Septin 9 gene by PCR amplification of DNA extracted from plasma was reported to detect 72% of colon cancers with a false positive rate of 10% (Grutzmann et al, 2008).
- the DNA methylation status of specific genes or loci is usually detected by selective bisulphite deamination of cytosine, but not 5-methylcytosine, to uracil, leading to a primary DNA sequence change that can be detected by sequencing or other means (Allen et al, 2004).
- Global DNA hypomethylation is a hallmark of cancer cells (Estellar 2007 and Hervouet et al, 2010).
- Global DNA methylation can be studied in cells using immunohistochemistry (IHC) techniques. Alternatively the DNA is extracted from the cells for analysis. A number of methods have been reported for the detection of global methylation in DNA extracted from cells or other media including restriction digestion and nearest-neighbour analysis, fluorescent assays using
- chloracetaldehyde inverse determination by methylation of all CpG sites using DNA methyltransferase in conjunction with tritium-labeled S-adenosyl methionine to calculate the amount of unmethylated CpG and digestion of DNA into single nucleotides for analysis by high-performance liquid chromatography, thin-layer chromatography, or liquid chromatography followed by mass spectroscopy.
- the disadvantages of these methods are that they are labour intensive and/or require large amounts of good quality extracted DNA (Allen et a/ 2004).
- PCR based methods involving bisulfite deamination overcome the need for large amounts of DNA but must amplify specific genome regions, typically repetitive sequences, as indicative of the total genome content of 5-methylcytosine (Allen et al 2004). These methods for global DNA methylation measurement have been used to study DNA extracted from a variety of cells and tissues. Some workers have studied DNA extracted from white blood cells in whole blood as this is easier to obtain in a minimally-invasive manner (Moore et al, 2008; Ting Hsiung et al, 2007; Mansour ei a/, 2010). Liquid
- Chromatography with mass spectrometry is considered the gold standard for global DNA methylation measurement but it is costly, and the DNA must be digested to the single nucleotide level prior to analysis (Vasser et al, 2009).
- Recent methods for the estimation of global DNA methylation include ultra high- pressure liquid chromatography with mass spectrometry of hydrolysed DNA extracted from tissue (Zhang et al, 201 1 ) and a methylation-specific digital sequencing (MSDS) method (Ogoshi et al 201 1 ).
- MSDS methylation-specific digital sequencing
- DNA extracted from tissues or from plasma or serum samples is coated to a microtitre well and methylated DNA is detected using an anti-5-methylcytosine antibody (Vasser, et al, 2009; Epigentek, 2009).
- a disadvantage of these methods is that they require extraction of DNA involving the denaturation and removal of all nucleosome and chromatin structure from the DNA. They thus cannot measure nucleosome bound nucleotides and are not suited for example; for the direct measurement of global DNA methylation in biological fluids such as tissue lysate, blood, plasma or serum without a DNA extraction step.
- 5-hydroxymethyl modification of cytosine bases in DNA has also been reported. The role of 5-hydroxymethylation is not yet well understood but it appears to be involved in gene regulation (Stroud et al, 201 1 ).
- a cell free nucleosome comprising a DNA base, nucleotide or nucleoside for use as a biomarker for the diagnosis of cancer, cardiomyopathy, systemic lupus erythematosus, colitis, chronic obstructive pulmonary disorder, Crohn's disease and rheumatoid arthritis.
- a method for detecting the presence of a nucleosome containing a DNA base, nucleotide or nucleoside in a sample which comprises the steps of:
- a method for detecting the presence of a nucleosome containing a DNA base, nucleotide or nucleoside in a sample which comprises the steps of:
- a method for detecting the presence of a nucleosome containing a DNA base, nucleotide or nucleoside in a sample which comprises the steps of:
- nucleosomes containing the DNA base, nucleotide or nucleoside in the sample are used to measure the presence of nucleosomes containing the DNA base, nucleotide or nucleoside in the sample.
- a method for detecting the presence of a nucleosome containing a DNA base, nucleotide or nucleoside in a cell which comprises the steps of:
- a method for detecting or diagnosing a disease status in an animal or a human subject which comprises the steps of:
- nucleotide or nucleoside in a body fluid of a subject and
- a method for assessment of an animal or a human subject for suitability for a medical treatment which comprises the steps of:
- nucleotide or nucleoside in a body fluid of the subject and
- a method for monitoring a treatment of an animal or a human subject which comprises the steps of: detecting or measuring nucleosomes containing a DNA base, nucleotide or nucleoside in a body fluid of the subject; repeating the detection or measurement of nucleosomes containing a DNA base, nucleotide or nucleoside in a body fluid of the subject on one or more occasions; and
- nucleosome associated DNA base nucleotide or nucleoside level detected as a parameter for any changes in the condition of the subject.
- a method for identifying a DNA base, nucleotide or nucleoside biomarker for detecting or diagnosing a disease status in an animal or a human subject which comprises the steps of:
- nucleotide or nucleoside in a body fluid of the subject comprising:
- nucleotide or nucleoside in a body fluid of a healthy subject or a control subject and
- biomarker identified by said method of the invention.
- kits for the detection of a nucleosome associated DNA base, nucleotide or nucleoside which comprises a ligand or binder specific for the DNA base, nucleotide or nucleoside or component part thereof, or a structural/shape mimic of the DNA base, nucleotide or nucleoside or component part thereof, together with instructions for use of the kit.
- FIG. 1 ELISA dose response curve for the detection of 5-methylcytosine
- Figure 3 Nucleosome levels detected for serum and EDTA plasma samples taken from 20 healthy volunteers using nucleosome ELISA methods of the current art.
- Figure 4. Cell-free nucleosome associated levels of histone variant mH2A1 .1 detected for serum and EDTA plasma samples taken from 20 healthy volunteers.
- P-H2AX(Ser139) detected for serum and EDTA plasma samples taken from 20 healthy volunteers.
- Figure 10 Cell-free nucleosome associated levels of nucleotides and types of histones detected for EDTA plasma samples taken from 3 colon cancer subjects. Cell-free nucleosome associated levels of nucleotides and types of histones detected for EDTA plasma samples taken from 13 lung cancer subjects.
- EDTA plasma samples taken from lung and colon cancer patients with increasing tumour size, stage and nodal development of disease were taken from lung and colon cancer patients with increasing tumour size, stage and nodal development of disease.
- Figure 20 Mean cell-free nucleosome associated levels of nucleotides and types of histones detected using ELISA methods of the invention for EDTA plasma samples taken from 10 different cancer diseases normalised as a proportion of nucleosome associated 5-methylcytosine (5mc) methylated DNA levels and expressed relative to the mean proportions found in 1 1 healthy subjects.
- 5mc nucleosome associated 5-methylcytosine
- Figure 21 Mean cell-free nucleosome associated levels of nucleotides and types of histones detected using ELISA methods of the invention for EDTA plasma samples taken from 2 cardiomyopathy patients, 10 systemic lupus erythematosus (lupus) patients, 12 ulcerative colitis patients, 10 chronic obstructive pulmonary disease (COPD) patients, 8 Crohn's disease patients and 10 rheumatoid arthritis (RA) patients normalised as a proportion of nucleosome associated 5-methylcytosine (5mc) methylated DNA levels and expressed relative to the mean proportions found in 1 1 healthy subjects.
- COPD chronic obstructive pulmonary disease
- RA rheumatoid arthritis
- the nucleosome is a mononucleosome or oligonucleosome.
- the cancer is a cancer of the bladder, breast, colon, cervix, esophagus, kidney, large intestine, lung, oral cavity, ovary, pancreas, prostate, rectum, skin or stomach.
- the cancer is a cancer of the colon, lung, oral cavity or pancreas.
- nucleosomes containing the DNA bases 5-methylcytosine and 5-hydroxymethylcytosine We have developed ELISA tests for the detection and measurement of nucleosomes containing the DNA bases 5-methylcytosine and 5-hydroxymethylcytosine. We have used an anti-histone antibody as capture antibody for these assays in combination with an appropriate specific anti-nucleotide antibody. We have used the assays to show that nucleosomes containing specific nucleotides can be measured in blood samples taken from subjects with cancer and are discriminating for use as noninvasive or minimally invasive biomarkers. The nucleosome associated DNA 5- methylcytosine levels, relative to levels of other nucleosome epitopes, detected in serum and plasma samples taken from diseased subjects differed from those detected in samples from healthy subjects.
- the pattern of levels of the nucleotides detected in nucleosomes in samples taken from subjects with different diseases was found to differ such that a differential diagnosis of disease was possible, particularly when the nucleosome associated nucleotide patterns were examined in combination with the patterns determined for nucleosomes containing different histone variants and histone modifications. It will be clear to those skilled in the art that inclusion of tests for nucleosomes containing different or additional nucleotides would be likely to improve the discrimination of differential diagnosis using such patterns.
- nucleosomes found in healthy subjects using the methods of the current art we measured nucleosomes in serum and plasma samples, taken from the 20 healthy subjects. Both methods of the current art produced higher signals in serum samples taken from healthy subjects than in plasma samples. The results are shown in Figure 3. This is consistent with published data that nucleosome levels are higher in serum than plasma ( * Holdenrieder et al, 2001 ).
- nucleosomes containing the modified nucleotide 5- methylcytosine were measured in the sera of 20 healthy subjects and in healthy bovine serum. The serum results were low or undetectable for all 20 healthy subjects.
- nucleosomes containing the modified nucleotide 5-methylcytosine were measured in EDTA plasma samples, taken from the 20 healthy subjects, and, surprisingly, higher signals were observed. High levels of cell free nucleosomes containing the modified nucleotide 5-methylcytosine were detected by methods of the present invention in healthy human EDTA plasma but lower levels were detected in healthy human serum as shown in Figure 8. Figures 4-9 show that similar results were obtained for other nucleosome structures.
- sample selection for the detection of cell free nucleosomes containing particular nucleotide structures involves several parameters. These include the low levels of cell free nucleosomes generally present in serum and heparin plasma samples taken from healthy subjects, the higher levels generally present in EDTA and citrate plasma samples taken from healthy subjects, the recommendation that serum samples containing cell free nucleosomes should be stabilised by the addition of EDTA after separation of the serum from the clot ( * Holdenreider et al, 2001 ), and the serum sampling protocol. Other stabilizing agents (for example protease inhibitors) may also be used.
- nucleosome associated H2AZ assay was 0 - 0.95. Using this cut-off level of 0.95; all 13 healthy subjects were negative for elevated nucleosome H2AZ levels.
- a positive result for elevated nucleosome H2AZ levels was found for 84% (46 of 55) of cancer samples (an overall clinical sensitivity of 84%) including 100% (8 of 8) of stomach 100% (5 of 5) of large intestinal, 67% (2 of 3) of rectal, 83% (5 of 6) of small cell lung, 79% (1 1 of 14) of non-small cell lung, 50% (3 of 6) breast, 100% (1 of 1 ) of ovarian, 100% (1 of 1 ) of pancreas, 80% (4 of 5) of prostate, 100% (1 of 1 ) kidney and 100% (5 of 5) oral cancer samples.
- a control sample is provided and the cut-off level for the assay to distinguish between positive or negative results is defined in relation to the result for the control sample. This could be any proportion equal to or above or below the level of the control sample result. Patient results below this level are considered negative and patient results above this level are considered positive. There may also be a "grey area" range of patient results very close to the cut-off level for which the decision is considered indeterminate and/or the test should be repeated.
- nucleosome associated mH2A1.1 assay the normal range was 0 - 0.91. Using this cut-off value all 13 healthy samples were negative and 64% (35 of 55) of cancer samples were positive. For the nucleosome associated P-
- nucleosome structures it is possible to use the pattern of nucleosome structures to improve the clinical utility of the invention. This may be done, for example, by lowering the cut-off point of the nucleosome associated 5-methylcytosine assay to mean + 1 standard deviation which gives a range of up to 1 .01. In this case the number of false negatives is reduced to 4 giving an improved clinical sensitivity of 93% (51 of 55) at the expense of an increase in false positive results for samples taken from healthy subjects from 0% to 23% (3 of 13). The results are shown in Figure 17.
- nucleosome profile can be used to distinguish between healthy and diseased patients as illustrated in Figures 20 and 21 where the relative proportions of various nucleosome structures in diseased patients are expressed relative to those found in healthy patients and patients with other non-cancer diseases. This shows that investigation of multiple nucleosome structures in a test panel can facilitate better clinical discrimination.
- the diagnostic specificity and/or sensitivity of the invention may by increased by combining data from more than one test in the form of ratios.
- use of the nucleosome associated P-H2AX:5-methylcytosine ratio increases the detection of true positive cancer cases from 55% (30 of 55) for nucleosome associated 5- methylcytosine alone, to 67% (37 of 55) at the 2 standard deviation cut-off level whilst maintaining 100% (13 of 13) of negative results for samples taken from healthy subjects.
- the invention provides a novel nucleosome ELISA method capable of detecting nucleosomes not detected by nucleosome assays of the current art.
- nucleosomes found in healthy subjects were found to be present in all the cancer and non-cancer diseases investigated and were found to have profiles that differed from those of healthy subjects.
- EDTA plasma samples taken from 2 cardiomyopathy patients 10 systemic lupus erythematosus (lupus) patients, 12 ulcerative colitis patients, 10 chronic obstructive pulmonary disease (COPD) patients, 8 Crohn's disease patients and 10 rheumatoid arthritis (RA) patients and normalised the levels of various nucleosome structures detected as a proportion of the mean nucleosome associated 5-methylcytosine levels and expressed the results relative to those found in 1 1 healthy subjects.
- COPD chronic obstructive pulmonary disease
- RA rheumatoid arthritis
- nucleosome structure profiles can be used as a diagnostic tool for the detection, prognosis prediction, monitoring and therapeutic efficacy prediction in a wide variety of non-cancer diseases.
- the results are shown in Figure 21.
- the levels of various nucleosome structures detected were normalised as a proportion of nucleosome associated 5-methylcytosine (5mc) methylated DNA levels and expressed relative to the mean proportions found in 1 1 healthy subjects.
- 5mc nucleosome associated 5-methylcytosine
- nucleosome structure profiles can be used as a diagnostic tool for the detection, prognosis prediction, monitoring and therapeutic efficacy prediction in cancer and other diseases.
- the results are shown in Figures 20 and 21 .
- methods of the current invention can also be employed to detect or measure cell free methylated DNA per se (as nucleosome associated DNA containing for example; 5-methylcytosine or 5-hydroxymethylcytosine) directly in biological fluids including blood, serum and plasma.
- the methods of the invention thus employed have advantages of simplicity and speed over methods for measuring methylated DNA of the current art, particularly as extraction of DNA is not involved or required.
- nucleic acid or DNA base or nucleic acid analogue or derivative in nucleosomes include, without limitation adenine, thymine, guanine, cytosine, uracil, inosine, xanthine, hypoxanthine, 7,8-dihydro-8-oxo-guanine and any derivatives or analogues of these.
- a common nucleotide for example without limitation; guanine, cytosine, thymine or adenine
- the method of the invention using an antibody to a common nucleotide will provide a method to bind and detect virtually all nucleosomes in a sample.
- the invention provides a novel method for the detection of nucleosomes per se in which
- the invention provides a novel method for the detection of all nucleosome associated DNA in which nucleosomes containing a common nucleotide are measured as a way of ensuring that all or most nucleosome bound DNA is detected.
- measurement of two or more DNA bases will provide the basis for the measurement of a ratio of the relative DNA content of those DNA bases.
- ratios for the relative levels of 5-methylcytosine and 5- hydroxymethylcytosine in samples in Figures 10-14
- Our data show that the relative levels of 5-methylcytosine and 5-hydroxymethylcytosine detectable differs in different types of cancers and may be used to distinguish such cancers. Other similar ratios would also be useful in the art.
- the method of the invention can be used to detect the proportion of the DNA which comprises any particular base (for example the percentage of DNA which is methylated in a sample).
- the methods of the present invention provide a simple and rapid method for measurement of the percentage DNA content of any base in a sample.
- the method can be used quickly and simply in multiple samples, for example blood samples.
- the methods of the invention can be used to detect and measure DNA bases in nucleosomes in any sample where such nucleosomes occur including, for example, samples obtained by digestion of chromatin extracted from cells.
- the method of the present invention is a successful method for the detection and measurement of nucleosome associated DNA containing particular nucleotides, that this method can also be used successfully as a method for the detection of nucleosomes per se and that it is a superior method for the detection of nucleosomes per se than the methods of the current art and that this method can also be used successfully as a method for the direct detection of cell free DNA per se and for the nucleotide composition of cell free DNA per se and that it is a superior method for the detection of nucleosome associated DNA and its nucleotide composition than the methods of the current art.
- the method is rapid, low cost and suitable for use in complex biological media and fluids.
- the method of the current invention can be used to detect nucleosomes and nucleosomes containing methylated DNA in blood, and that this may be used as a biomarker for cancer. It will be clear to those skilled in the art that a biomarker present in the blood samples taken from cancer patients has value for a broad range of diagnostic and disease screening purposes for cancer and other diseases which are associated with elevated circulating nucleosomes (Holdenrieder ei a/, 2001 ). To confirm that elevated levels of nucleosomes are not found in healthy subjects using the methods of the invention we measured nucleosomes containing the nucleotides 5-methylcytosine and 5-hydroxymethylcytosine in the sera of 20 healthy subjects and in healthy bovine serum.
- the invention has been tested on many cancer and non-cancer diseases and has been found effective in the detection of all the diseases tested. This includes the detection of prostate cancer cases which is not detectable by the nucleosome ELISA tests of the current art (Holdenrieder, 2001 ). It is clear that the invention is effective for the detection of all or most cancers. It will be clear to those skilled in the art that the clinical performance of the invention may be improved further by inclusion of further nucleosome structure tests and by examination of the ratios of different nucleosome structures present.
- a double antibody, immunometric or sandwich immunoassay method for detecting and measuring cell free nucleosomes containing nucleotides in a sample.
- an immunoassay which comprises the steps of:
- Immunometric immunoassays employ an antibody (or other binder) to bind the analyte.
- the analyte thus bound is detected as a direct measure of its level or concentration in the original test sample.
- competitive immunoassays often use a much smaller amount of antibody (or other binder) to bind a proportion of the analyte and a labelled analyte (or analyte analogue) preparation is employed to distribute between the bound and free analyte fractions (with the sample analyte).
- the amount of bound labelled analyte is measured as an indirect measure of the analyte concentration in the original sample.
- a labelled antibody is employed, together with a solid phase analyte (or analyte analogue) preparation.
- the binding of the labelled antibody is distributed between the sample analyte and the solid phase analyte (or analyte analogue).
- the amount of antibody bound to the solid phase analyte (or analyte analogue) preparation is used as an indirect measure of the analyte concentration of the sample.
- a method for detecting and measuring a nucleotide, including a nucleosome associated nucleotide, in a sample by a label-free immunometric immunoassay which comprises the steps of:
- a fourth embodiment of the invention there is provided a method for detecting and measuring a nucleotide, including a nucleosome associated nucleotide, in a sample by a competitive immunoassay which comprises the steps of:
- nucleotide immunoassay methods of the invention measure nucleotides and nucleosome associated nucleotides directly without any requirement for extraction of DNA.
- nucleotide immunoassay methods of the current art detect (non-nucleosome associated) nucleotides after extraction of DNA from a sample.
- the methods of the invention have advantages of speed, simplicity and suitability for direct measurements in complex biological samples including blood or its derivatives.
- both the cell free DNA level in the sample and the nucleotide of interest are measured using the method of the invention.
- the nucleotide of interest is a methylated cytosine nucleotide and the proportion of the DNA that comprises the nucleotide provides a measure of global DNA methylation.
- nucleosomes containing nucleotides in the blood taken from subjects can be used as a diagnostic method to identify subjects with cancer and to differentiate them from healthy subjects.
- a method for detecting or diagnosing the presence of a disease by measuring or detecting the presence and/or the level or concentration of cell free nucleosomes containing a nucleotide in a body fluid, and using the detected level as a biomarker of the disease status of a subject including, without limitation, a clinical diagnosis of a disease, a differential diagnosis of disease type or subtype, or a disease prognosis, or a disease relapse, or a diagnosis of subject susceptibility to treatment regimens.
- body fluids used for diagnostic testing include without limitation blood, serum, plasma, urine, cerebrospinal fluid and other fluids.
- the body fluid selected as the sample is blood, serum or plasma.
- the assay response, level, concentration or quantity of a nucleosome associated nucleotide in a body fluid may be expressed in absolute terms or relative terms, for example without limitation as a proportion of the total nucleosome level present or as a ratio to the level of nucleosomes containing another nucleotide or histone variant or histone PTM or to the level of total DNA.
- the nucleosome associated nucleotide measurement is used as a member of a diagnostic panel of tests or measurements for the detection or diagnosis of the disease status of a subject including, without limitation, a clinical diagnosis of a disease, a differential diagnosis of disease type or subtype, or a disease prognosis, or a disease relapse, or a diagnosis of subject susceptibility to treatment regimens
- nucleosome associated DNA As all or most circulating cell free DNA is reported to exist as nucleosome associated DNA, it will be clear to those skilled in the art that diagnosis or detection of disease state can be achieved by detection or measurement of nucleotides per se using a direct nucleotide immunoassay of the invention with no DNA extraction step in a biological fluid, rather than, or in addition to, an immunoassay for nucleosome associated nucleotides.
- a non-extraction nucleotide immunoassay method for detecting or diagnosing the presence of a disease by measuring or detecting the presence and/or the level or concentration of a nucleotide in a body fluid, and using the detected level as a biomarker (either alone as a member of a panel of tests) of the disease status of a subject including, without limitation, a clinical diagnosis of a disease, a differential diagnosis of disease type or subtype, or a disease prognosis, or a disease relapse, or a diagnosis of subject susceptibility to treatment regimens.
- body fluids used for diagnostic testing include without limitation blood, serum, plasma, urine, cerebrospinal fluid and other fluids.
- the body fluid selected as the sample is blood, serum or plasma.
- the assay response, level, concentration or quantity of a nucleotide in a body fluid may be expressed in absolute terms or relative terms, for example without limitation as a proportion of the total nucleosome level present or as a ratio to the level of another nucleotide or histone variant or histone PTM or to the level of total DNA.
- a method for detecting or measuring the presence and/or the level of nucleosomes containing a nucleotide in a cell which comprises the steps of:
- nucleotide selected for detection by the method is a commonly occurring nucleotide that occurs in all or most intact nucleosomes, providing a method for the detection or measurement of nucleosomes per se.
- nucleotide selected for detection by the method is a commonly occurring nucleotide that occurs in all or most intact nucleosomes, providing a method for the detection or measurement of nucleosome bound DNA.
- nucleosome associated nucleotides in cells or tissues has advantages over currently used methods including IHC, or detecting nucleotides in DNA extracted from cells by restriction digestion and nearest-neighbour analysis, or by fluorescent assays using chloracetaldehyde, or by inverse determination by methylation of all CpG sites using DNA methyltransferase in conjunction with tritium-labeled S-adenosyl methionine to calculate the amount of unmethylated CpG, or by digestion of DNA into single nucleotides for analysis by high-performance liquid chromatography, thin-layer chromatography, or liquid chromatography followed by mass spectroscopy.
- the level, concentration or quantity of a particular nucleosome associated nucleotide may be expressed in absolute terms or relative terms, for example as a proportion of the total nucleosomes present or as a ratio to the total level of nucleosomes or to the level of nucleosomes containing another nucleotide or histone variant or histone PTM, or to the total level of DNA.
- antibody, binder or ligand in regard to any aspect of the invention is not limiting but intended to include any binder capable of binding to particular molecules or entities and that any suitable binder can be used in the method of the invention.
- nucleosomes is intended to include mononucleosomes and oligonucleosomes and any such chromatin fragments that can be analysed in fluid media.
- kits for detecting or measuring nucleosomes which comprises a ligand or binder specific for the nucleotide or a component part thereof, or a structural/shape mimic of the nucleosome or component part thereof, together with instructions for use of the kit in accordance with any of the methods defined herein.
- kits for detecting or measuring nucleosomes containing a nucleotide which comprises a ligand or binder specific for the nucleotide or a component part thereof, or a structural/shape mimic of the nucleotide or component part thereof, together with instructions for use of the kit in accordance with any of the methods defined herein.
- a method for identifying a nucleosome associated nucleotide biomarker or a nucleotide biomarker for detecting or diagnosing disease status in animals or humans which comprises the steps of:
- control subjects may be selected on a variety of basis which may include, for example, subjects known to be free of the disease or may be subjects with a different disease (for example; for the investigation of differential diagnosis).
- a method for identifying a nucleosome associated nucleotide biomarker or a nucleotide biomarker for assessing the prognosis of a diseased animal or human subject which comprises the steps of:
- a biomarker identified by the method as defined herein.
- nucleotide contained within a nucleosome is detected directly in a biological fluid including blood, plasma, serum and urine by use of an immunoassay method for a nucleotide.
- a nucleosome associated nucleotide is detected directly without prior extraction in a biological fluid including blood, plasma, serum and urine using an immunoassay for the nucleotide.
- a further aspect of the invention provides ligands or binders, such as naturally occurring or chemically synthesised compounds, capable of specific binding to the biomarker.
- a ligand or binder according to the invention may comprise a peptide, an antibody or a fragment thereof, or a synthetic ligand such as a plastic antibody, or an aptamer or oligonucleotide, capable of specific binding to the biomarker.
- the antibody can be a monoclonal antibody or a fragment thereof capable of specific binding to the biomarker.
- a ligand according to the invention may be labeled with a detectable marker, such as a luminescent, fluorescent, enzyme or radioactive marker; alternatively or additionally a ligand according to the invention may be labelled with an affinity tag, e.g. a biotin, avidin, streptavidin or His (e.g. hexa-His) tag. Alternatively ligand binding may be determined using a label-free technology for example that of ForteBio Inc.
- a biosensor according to the invention may comprise the biomarker or a structural/shape mimic thereof capable of specific binding to an antibody against the biomarker. Also provided is an array comprising a ligand or mimic as described herein.
- Also provided by the invention is the use of one or more ligands as described herein, which may be naturally occurring or chemically synthesised, and is suitably a peptide, antibody or fragment thereof, aptamer or oligonucleotide, or the use of a biosensor of the invention, or an array of the invention, or a kit of the invention to detect and/or quantify the biomarker.
- the detection and/or quantification can be performed on a biological sample as defined herein.
- kits for performing methods of the invention.
- Such kits will suitably comprise a ligand according to the invention, for detection and/or quantification of the biomarker, and/or a biosensor, and/or an array as described herein, optionally together with instructions for use of the kit.
- a further aspect of the invention is a kit for detecting the presence of a disease state, comprising a biosensor capable of detecting and/or quantifying one or more of the biomarkers as defined herein.
- Biomarkers for detecting the presence of a disease are essential targets for discovery of novel targets and drug molecules that retard or halt progression of the disorder. As the level of the biomarker is indicative of disorder and of drug response, the biomarker is useful for identification of novel therapeutic compounds in in vitro and/or in vivo assays. Biomarkers of the invention can be employed in methods for screening for compounds that modulate the activity of the biomarker.
- a binder or ligand as described, which can be a peptide, antibody or fragment thereof or aptamer or oligonucleotide according to the invention; or the use of a biosensor according to the invention, or an array according to the invention; or a kit according to the invention, to identify a substance capable of promoting and/or of suppressing the generation of the biomarker.
- Also there is provided a method of identifying a substance capable of promoting or suppressing the generation of the biomarker in a subject comprising administering a test substance to a subject animal and detecting and/or quantifying the level of the biomarker present in a test sample from the subject.
- detecting and diagnosis encompass identification, confirmation, and/or characterisation of a disease state.
- Methods of detecting, monitoring and of diagnosis according to the invention are useful to confirm the existence of a disease, to monitor development of the disease by assessing onset and progression, or to assess amelioration or regression of the disease.
- Methods of detecting, monitoring and of diagnosis are also useful in methods for assessment of clinical screening, prognosis, choice of therapy, evaluation of therapeutic benefit, i.e. for drug screening and drug development.
- Efficient diagnosis and monitoring methods provide very powerful "patient solutions” with the potential for improved prognosis, by establishing the correct diagnosis, allowing rapid identification of the most appropriate treatment (thus lessening unnecessary exposure to harmful drug side effects), and reducing relapse rates.
- said biomarker is released from the cells of a tumour.
- a method for the detection of a tumour growth which comprises the steps of (i) measuring a biomarker in a biological sample that is associated with or released from the cells of a tumour and (ii) demonstrating that the level of said biomarker is associated with the size, stage, aggressiveness or dissemination of the tumour.
- Circulating cell free nucleosomes level is a non-specific indicator and occurs in a variety of conditions including inflammatory diseases, a large variety of benign and malignant conditions, autoimmune diseases, as well as following trauma or ischaemia (Holdenrieder et al 2001 ). It will be clear to those skilled in the art that the invention will have application in a variety of disease areas where circulating nucleosomes have been found in subjects.
- the immunoassay method of the invention to measure nucleosome levels and investigate their nucleotide and histone structure variability in a variety of such diseases including cardiomyopathy, systemic lupus erythematosus, ulcerative colitis, chronic obstructive pulmonary disease, Crohn's disease and rheumatoid arthritis and compared these with the results of healthy subjects.
- the methods of the current invention are capable of detection of a wider range of nucleosomes than current nucleosome ELISA methods, the methods of the invention have applications in a wide range of cancer and non-cancer disease areas.
- the immunoassays of the invention include immunometric assays employing enzyme detection methods (for example ELISA), fluorescence labelled immunometric assays, time-resolved fluorescence labelled immunometric assays, chemiluminescent immunometric assays, immunoturbidimetric assays, particulate labelled
- immunometric assays and immunoradiometric assays and competitive immunoassay methods including labelled antigen and labelled antibody competitive immunoassay methods with a variety of label types including radioactive, enzyme, fluorescent, time- resolved fluorescent and particulate labels. All of said immunoassay methods are well known in the art, see for example Salgame et al, 1997 and van Nieuwenhuijze et al, 2003.
- said biological sample comprises a body fluid.
- biological samples that may be tested in a method of the invention include cerebrospinal fluid (CSF), whole blood, blood serum, plasma, menstrual blood, endometrial fluid, urine, saliva, or other bodily fluid (stool, tear fluid, synovial fluid, sputum), breath, e.g. as condensed breath, or an extract or purification therefrom, or dilution thereof.
- CSF cerebrospinal fluid
- whole blood blood serum, plasma, menstrual blood, endometrial fluid, urine, saliva, or other bodily fluid (stool, tear fluid, synovial fluid, sputum), breath, e.g. as condensed breath, or an extract or purification therefrom, or dilution thereof.
- Biological samples also include specimens from a live subject, or taken post-mortem. The samples can be prepared, for example where appropriate diluted or concentrated, and stored in the usual manner.
- the method of the invention is repeated on multiple occasions. This embodiment provides
- the invention also provides a method of monitoring efficacy of a therapy for a disease state in a subject, suspected of having such a disease, comprising detecting and/or quantifying the biomarker present in a biological sample from said subject.
- test samples may be taken on two or more occasions.
- the method may further comprise comparing the level of the biomarker(s) present in the test sample with one or more control(s) and/or with one or more previous test sample(s) taken earlier from the same test subject, e.g. prior to commencement of therapy, and/or from the same test subject at an earlier stage of therapy.
- the method may comprise detecting a change in the nature or amount of the biomarker(s) in test samples taken on different occasions.
- a method for monitoring efficacy of therapy for a disease state in a human or animal subject comprising:
- a change in the level of the biomarker in the test sample relative to the level in a previous test sample taken earlier from the same test subject may be indicative of a beneficial effect, e.g. stabilisation or improvement, of said therapy on the disorder or suspected disorder.
- the method of the invention may be periodically repeated in order to monitor for the recurrence of a disease.
- Methods for monitoring efficacy of a therapy can be used to monitor the therapeutic effectiveness of existing therapies and new therapies in human subjects and in non- human animals (e.g. in animal models). These monitoring methods can be incorporated into screens for new drug substances and combinations of substances. In a further embodiment the monitoring of more rapid changes due to fast acting therapies may be conducted at shorter intervals of hours or days.
- a method for identifying a biomarker for detecting the presence of a disease state means confirming the presence of the biomarker present in the biological sample. Quantifying the amount of the biomarker present in a sample may include determining the concentration of the biomarker present in the sample. Identifying and/or quantifying may be performed directly on the sample, or indirectly on an extract therefrom, or on a dilution thereof.
- the presence of the biomarker is assessed by detecting and/or quantifying antibody or fragments thereof capable of specific binding to the biomarker that are generated by the subject's body in response to the biomarker and thus are present in a biological sample from a subject having a disease state.
- Identifying and/or quantifying can be performed by any method suitable to identify the presence and/or amount of a specific protein in a biological sample from a patient or a purification or extract of a biological sample or a dilution thereof.
- quantifying may be performed by measuring the concentration of the biomarker in the sample or samples.
- Biological samples that may be tested in a method of the invention include those as defined hereinbefore. The samples can be prepared, for example where appropriate diluted or concentrated, and stored in the usual manner.
- Identification and/or quantification of biomarkers may be performed by detection of the biomarker or of a fragment thereof, e.g. a fragment with C-terminal truncation, or with N-terminal truncation. Fragments are suitably greater than 4 amino acids in length, for example 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. It is noted in particular that peptides of the same or related sequence to that of histone tails are particularly useful fragments of histone proteins.
- the biomarker may be directly detected, e.g. by SELDI or MALDI-TOF.
- the biomarker may be detected directly or indirectly via interaction with a ligand or ligands such as an antibody or a biomarker-binding fragment thereof, or other peptide, or ligand, e.g. aptamer, or oligonucleotide, capable of specifically binding the biomarker.
- a ligand or ligands such as an antibody or a biomarker-binding fragment thereof, or other peptide, or ligand, e.g. aptamer, or oligonucleotide, capable of specifically binding the biomarker.
- the ligand or binder may possess a detectable label, such as a luminescent, fluorescent or radioactive label, and/or an affinity tag.
- detecting and/or quantifying can be performed by one or more method(s) selected from the group consisting of: SELDI (-TOF), MALDI (-TOF), a 1 -D gel-based analysis, a 2-D gel-based analysis, Mass spec (MS), reverse phase (RP) LC, size permeation (gel filtration), ion exchange, affinity, HPLC, UPLC and other LC or LC MS-based techniques.
- SELDI SELDI
- MALDI MALDI
- MS mass spec
- RP reverse phase
- size permeation gel filtration
- ion exchange affinity
- HPLC HPLC
- UPLC UPLC
- LC MS-based techniques e.g.
- Methods of diagnosing or monitoring according to the invention may comprise analysing a sample by SELDI TOF or MALDI TOF to detect the presence or level of the biomarker. These methods are also suitable for clinical screening, prognosis, monitoring the results of therapy, identifying patients most likely to respond to a particular therapeutic treatment, for drug screening and development, and identification of new targets for drug treatment.
- Identifying and/or quantifying the analyte biomarkers may be performed using an immunological method, involving an antibody, or a fragment thereof capable of specific binding to the biomarker.
- Suitable immunological methods include sandwich immunoassays, such as sandwich ELISA, in which the detection of the analyte biomarkers is performed using two antibodies which recognize different epitopes on a analyte biomarker; radioimmunoassays (RIA), direct, indirect or competitive enzyme linked immunosorbent assays (ELISA), enzyme immunoassays (EIA), Fluorescence immunoassays (FIA), western blotting, immunoprecipitation and any particle-based immunoassay (e.g. using gold, silver, or latex particles, magnetic particles, or Q- dots).
- Immunological methods may be performed, for example, in microtitre plate or strip format.
- one or more of the biomarkers may be replaced by a molecule, or a measurable fragment of the molecule, found upstream or downstream of the biomarker in a biological pathway.
- the identification of key biomarkers specific to a disease is central to integration of diagnostic procedures and therapeutic regimes.
- appropriate diagnostic tools such as biosensors can be developed; accordingly, in methods and uses of the invention, identifying and quantifying can be performed using a biosensor, microanalytical system, microengineered system, microseparation system, immunochromatography system or other suitable analytical devices.
- the biosensor may incorporate an immunological method for detection of the biomarker(s), electrical, thermal, magnetic, optical (e.g. hologram) or acoustic technologies. Using such biosensors, it is possible to detect the target biomarker(s) at the anticipated concentrations found in biological samples.
- biosensor means anything capable of detecting the presence of the biomarker. Examples of biosensors are described herein. Biosensors according to the invention may comprise a ligand binder or ligands, as described herein, capable of specific binding to the biomarker. Such biosensors are useful in detecting and/or quantifying a biomarker of the invention.
- biomarker(s) of the invention can be detected using a biosensor incorporating technologies based on "smart" holograms, or high frequency acoustic systems, such systems are particularly amenable to "bar code” or array configurations.
- a holographic image is stored in a thin polymer film that is sensitised to react specifically with the biomarker.
- the biomarker reacts with the polymer leading to an alteration in the image displayed by the hologram.
- the test result read-out can be a change in the optical brightness, image, colour and/or position of the image.
- a sensor hologram can be read by eye, thus removing the need for detection equipment.
- a simple colour sensor can be used to read the signal when quantitative measurements are required. Opacity or colour of the sample does not interfere with operation of the sensor.
- the format of the sensor allows multiplexing for simultaneous detection of several substances. Reversible and irreversible sensors can be designed to meet different requirements, and continuous monitoring of a particular biomarker of interest is feasible.
- biosensors for detection of one or more biomarkers of the invention combine biomolecular recognition with appropriate means to convert detection of the presence, or quantitation, of the biomarker in the sample into a signal.
- Biosensors can be adapted for "alternate site" diagnostic testing, e.g. in the ward, outpatients' department, surgery, home, field and workplace.
- Biosensors to detect one or more biomarkers of the invention include acoustic, plasmon resonance, holographic, Bio-Layer Interferometry (BLI) and microengineered sensors. Imprinted recognition elements, thin film transistor technology, magnetic acoustic resonator devices and other novel acousto-electrical systems may be employed in biosensors for detection of the one or more biomarkers of the invention.
- biomarkers of the invention can be performed on bench-top instruments, or can be incorporated onto disposable, diagnostic or monitoring platforms that can be used in a non- laboratory environment, e.g. in the physician's office or at the patient's bedside.
- Suitable biosensors for performing methods of the invention include "credit" cards with optical or acoustic readers. Biosensors can be configured to allow the data collected to be electronically transmitted to the physician for interpretation and thus can form the basis for e-medicine.
- kits for the diagnosis and monitoring of the presence of a disease state are described herein.
- the kits additionally contain a biosensor capable of identifying and/or quantifying a biomarker.
- a kit according to the invention may contain one or more components selected from the group: a ligand binder, or ligands, specific for the biomarker or a structural/shape mimic of the biomarker, one or more controls, one or more reagents and one or more consumables; optionally together with instructions for use of the kit in accordance with any of the methods defined herein.
- the identification of biomarkers for a disease state permits integration of diagnostic procedures and therapeutic regimes.
- biomarker of the invention can be used to screen subjects prior to their participation in clinical trials.
- the biomarkers provide the means to indicate therapeutic response, failure to respond, unfavourable side-effect profile, degree of medication compliance and achievement of adequate serum drug levels.
- the biomarkers may be used to provide warning of adverse drug response. Biomarkers are useful in development of personalized therapies, as assessment of response can be used to fine-tune dosage, minimise the number of prescribed medications, reduce the delay in attaining effective therapy and avoid adverse drug reactions.
- biomarker of the invention can be used to titrate the optimal dose, predict a positive therapeutic response and identify those patients at high risk of severe side effects.
- Biomarker-based tests provide a first line assessment of 'new' patients, and provide objective measures for accurate and rapid diagnosis, not achievable using the current measures.
- diagnostic biomarker tests are useful to identify family members or patients with mild or asymptomatic disease or who may be at high risk of developing symptomatic disease. This permits initiation of appropriate therapy, or preventive measures, e.g. managing risk factors. These approaches are recognised to improve outcome and may prevent overt onset of the disorder.
- Biomarker monitoring methods, biosensors and kits are also vital as patient monitoring tools, to enable the physician to determine whether relapse is due to worsening of the disorder. If pharmacological treatment is assessed to be inadequate, then therapy can be reinstated or increased; a change in therapy can be given if appropriate. As the biomarkers are sensitive to the state of the disorder, they provide an indication of the impact of drug therapy.
- a commercially available nucleosome preparation produced by digestion of chromatin extracted from MCF7 cells in which the DNA and proteins in the
- nucleosomes are cross-linked for stability (ensuring that all histones present in the preparation are incorporated into intact nucleosomes) was assayed for methylated DNA using an ELISA method for the nucleosome associated nucleotide 5- methylcytosine using a solid phase anti-histone capture antibody that binds intact nucleosomes and a biotinylated monoclonal anti-5-methylcytosine detection antibody.
- the nucleosome sample was serially diluted in fetal calf serum and was tested in duplicate in the ELISA. Neat fetal calf serum was also run in the ELISA as a control sample containing no cell free nucleosomes.
- the assay method was as follows: A solution of anti-histone antibody in 0.1 M phosphate buffer pH 7.4 was added to microtitre wells (100 ⁇ -Jwell) and incubated overnight at 4°C to coat the wells with capture antibody. Excess anti-histone antibody was decanted. A solution of bovine serum albumin (20g/L) was added to the wells (200 ⁇ -Jwell) and incubated 30 minutes at room temperature to block excess protein binding sites on the wells.
- a solution of biotinylated anti-5-methylcytosine detection antibody was added (50 ⁇ -Jwell) and incubated 90 minutes at room temperature with mild agitation. Excess detection antibody was decanted and the wells were again washed three times with wash buffer (200 ⁇ _ ⁇ ⁇ ).
- a solution containing a streptavidin-horse radish peroxidase conjugate was added (50 L/well) and incubated 30 minutes at room temperature with mild agitation. Excess conjugate was decanted and the wells were again washed three times with wash buffer (200 ⁇ -Jwell).
- a coloured substrate solution 100 ⁇ -Jwell, 2,2'- Azinobis [3-ethylbenzothiazoline-6-sulfonic acidj-diammonium salt) was added and incubated 20 minutes at room temperature with mild agitation.
- the optical density (OD) of the wells was measured at a wavelength of 405nm using a standard microtitre plate reader.
- a dose response curve of increasing colour with increasing nucleosome associated anti-5-methylcytosine concentration was observed with a low background signal observed in the absence of 5-methylcytosine (fetal calf serum).
- the positive ELISA signal indicates that the 5-methylcytosine detected by the ELISA is incorporated within an intact nucleosome comprising both histone protein and DNA as (i) the capture antibody binds to histones in the sample and (ii) detection antibody binds to the 5-methylcytosine component of DNA.
- the results are shown in Figure 1 .
- a commercially available nucleosome preparation produced by digestion of chromatin extracted from A375 cells in which the DNA and proteins in the
- nucleosomes are cross-linked for stability (ensuring that all histones present in the preparation are incorporated into intact nucleosomes) was assayed for 5- hydroxymethylated DNA using an ELISA method for the nucleosome associated nucleotide 5-hydroxymethylcytosine using a solid phase anti-histone capture antibody that binds intact nucleosomes and a biotinylated monoclonal anti-5- hydroxymethylcytosine detection antibody.
- the nucleosome sample was serially diluted in fetal calf serum and was tested in duplicate in the ELISA. Neat fetal calf serum was also run in the ELISA as a control sample containing no cell free nucleosomes.
- the assay method was as follows: A solution of anti-histone antibody in 0.1 M phosphate buffer pH 7.4 was added to microtitre wells (100 ⁇ -Jwell) and incubated overnight at 4°C to coat the wells with capture antibody. Excess anti- histone antibody was decanted. A solution of bovine serum albumin (20g/L) was added to the wells (200 ⁇ -Jwell) and incubated 30 minutes at room temperature to block excess protein binding sites on the wells. Excess bovine serum albumin solution was decanted and the wells were washed three times with wash buffer (200 ⁇ -Jwell, 0.05M TRIS/HCI buffer pH 7.5 containing 1 % Tween 20).
- Sample (10 MlJwell) and assay buffer 50 Uwell, 0.05M TRIS/HCI pH 7.5 containing 0.9% NaCI, 0.05% sodium deoxycholate and 1 % Nonidet P40 substitute) were added to the wells incubated 90 minutes at room temperature with mild agitation.
- the sample and assay buffer mixture was decanted and the wells were washed three times with wash buffer (200 ⁇ -Jwell).
- a solution of biotinylated anti-5-hydroxymethylcytosine detection antibody was added (50 ⁇ -Jwell) and incubated 90 minutes at room temperature with mild agitation. Excess detection antibody was decanted and the wells were again washed three times with wash buffer (200 L/well).
- a solution containing a streptavidin-horse radish peroxidase conjugate was added (50 ⁇ -Jwell) and incubated 30 minutes at room temperature with mild agitation. Excess conjugate was decanted and the wells were again washed three times with wash buffer (200 ⁇ _ ⁇ ⁇ ).
- a coloured substrate solution 100 L/well, 2,2'-Azinobis [3- ethylbenzothiazoline-6-sulfonic acidj-diammonium salt) was added and incubated 20 minutes at room temperature with mild agitation.
- the optical density (OD) of the wells was measured at a wavelength of 405nm using a standard microtitre plate reader.
- the first current ELISA method was the Roche Cell Death ELISA and the other (ELISA 2) an ELISA employing an anti-histone capture antibody and an anti-histone-DNA complex detection antibody.
- the nucleosome levels detected by both current nucleosome ELISA methods were lower in normal plasma than in normal serum.
- the normal range (expressed in optical density units) for the serum level of nucleosomes was calculated (mean ⁇ 2 standard deviations of the mean of the 20 healthy subject serum results) to be 0 - 4.3 OD units for ELISA 1 and 0 - 1 .4 for ELISA 2.
- the respective ranges for plasma were 0 - 0.95 and 0 - 0.96.
- the results are shown in Figure 3.
- the normal ranges (expressed as optical density) for the serum level of nucleosomes containing histone variants, PTM or nucleotides were; (a) 0 - 0.36 for mH2A1 .1 , (b) 0.05 - 0.78 for mH2A2, (c) 0.1 1 - 0.58 for H2AZ, (d) 0.06 - 0.61 for P-H2AX(Ser139), (e) 0.06-0.36 for 5-methylcytosine and (f) 0.03-0.36 for 5-hydroxymethylcytrosine.
- the measured EDTA plasma results were higher for all 20 healthy subjects. The results are shown in Figures 4, 5, 6, 7, 8 and 9. EXAMPLE 4
- ELISA 1 The first current ELISA method was the Roche Cell Death ELISA and the other (ELISA 2) an ELISA employing an anti-histone capture antibody and an anti-histone-DNA complex detection antibody.
- nucleosome levels containing different nucleotide, histone variant and histone PTM levels is not uniform for all subjects but displays different patterns for different cancers tested.
- results for the nucleosome tests for nucleosomes containing macroH2A1 .1 , macroH2A2, H2AZ, P-H2AX(Ser139), 5- methylcytosine, 5-hydroxymethylcytosine
- the normalised results are shown for each cancer in Figure 14 as well as the same results for the nucleosome sample produced from healthy subjects (mH2A2 and 5-hydroxymethylcytosine were not measured for this sample).
- Figure 14 shows that the distribution pattern of nucleosomes containing the different normalised nucleotides, histone variants or PTM in all four cancers investigated differs quite markedly to the distribution of nucleosomes in the sample prepared from healthy subjects. For example the relative level of nucleosomes containing macroH2A1.1 in the healthy nucleosome sample differs from that detected in the samples of any of the cancer types.
- the present invention can be used as a method for the detection of cancer in a simple blood based screening test. It will be clear to those skilled in the art that the invention includes the testing of nucleosomes containing other further nucleotides and/or histone variants and/or histone modifications to further or better discriminate between circulating cell free
- nucleosomes of tumour or other disease origin are nucleosomes of tumour or other disease origin.
- the pattern of nucleosome types observed differs for different cancer types.
- the samples taken from subjects with colon, pancreatic and oral cancer can be distinguished by different normalised levels of nucleosome associated H2AZ and 5-hydroxymethylcytosine.
- oral cancer has different normalised levels of both nucleosomes containing mH2A2 or P-H2AX(Ser139) than any of the other three cancer types and samples from subjects with pancreatic cancer can be distinguished from samples from subjects with colon cancer on the basis of a different relative level of nucleosomes containing variant macroH2A1 .1 .
- the present invention can be used as a method to diagnose cancer generally and to distinguish a particular cancer type.
- the invention includes the testing of nucleosomes containing other further histone variants and/or histone modifications and/or nucleotides to further or better discriminate between circulating cell free nucleosomes of different specific tumour origin or other disease origin.
- nucleosome associated 5-methylcytosine levels were measured. The levels detected were correlated with the disease progression of the patients. The results shown in Figure 19 indicate that nucleosome associated 5-methylcytosine levels increase with severity of disease in terms of size, stage, nodal spread and nucleosome associated 5-methylcytosine levels may be used, alone or as part of a diagnostic panel, as indicators of disease progression, REFERENCES
- Kapoor ei a/ The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature: 468, 1 105-1 1 1 1 , 2010
- Vasser et al Measurement of Global DNA Methylation. Genetic Engineering and Biotechnology News: 29(7), 2009 Whittle et al, The Genomic Distribution and Function of Histone Variant HTZ-1 during C. elegans Embryogenesis. PLoS Genet 4(9): 1 -17, 2008
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014002443A MX364410B (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides. |
BR112014005087-2A BR112014005087B1 (en) | 2011-09-01 | 2012-08-31 | use of a dna base associated with a cell-free nucleosome as a biomarker, methods for detecting a dna base, as well as methods for detecting a disease state in an animal or human being, to assess adaptation to medical treatment , and for monitoring a medical treatment, and kit |
EP12756549.7A EP2751568B1 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
KR1020147008108A KR102074528B1 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
DK12756549.7T DK2751568T3 (en) | 2011-09-01 | 2012-08-31 | METHOD FOR DETECTING NUCLEOSOMES CONTAINING NUCLEOTIDES |
CA2845993A CA2845993C (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
US14/239,783 US10900064B2 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
RU2014112350/15A RU2014112350A (en) | 2011-09-01 | 2012-08-31 | METHOD FOR DETECTING NUCLEOSOMES CONTAINING NUCLEOTIDES |
ES12756549T ES2717659T3 (en) | 2011-09-01 | 2012-08-31 | Procedure for the detection of nucleosomes containing nucleotides |
SG11201400270PA SG11201400270PA (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
JP2014527737A JP6322845B2 (en) | 2011-09-01 | 2012-08-31 | Nucleotide-containing nucleosome detection method |
AU2012300641A AU2012300641B2 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
CN201280053555.1A CN104067124B (en) | 2011-09-01 | 2012-08-31 | Method for detecting the nucleosome containing nucleotide |
PL12756549T PL2751568T3 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
EP18212025.3A EP3483608B1 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
ZA2014/01295A ZA201401295B (en) | 2011-09-01 | 2014-02-20 | Method for detecting nucleosomes containing nucleotides |
HK15100175.0A HK1199760A1 (en) | 2011-09-01 | 2015-01-08 | Method for detecting nucleosomes containing nucleotides |
HRP20190533TT HRP20190533T1 (en) | 2011-09-01 | 2019-03-19 | Method for detecting nucleosomes containing nucleotides |
US16/875,856 US20200347435A1 (en) | 2011-09-01 | 2020-05-15 | Method for detecting nucleosomes containing nucleotides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161530295P | 2011-09-01 | 2011-09-01 | |
US61/530,295 | 2011-09-01 | ||
GB1115095.0 | 2011-09-01 | ||
GBGB1115095.0A GB201115095D0 (en) | 2011-09-01 | 2011-09-01 | Method for detecting nucleosomes containing nucleotides |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/239,783 A-371-Of-International US10900064B2 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
US16/875,856 Continuation US20200347435A1 (en) | 2011-09-01 | 2020-05-15 | Method for detecting nucleosomes containing nucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013030577A1 true WO2013030577A1 (en) | 2013-03-07 |
Family
ID=44882046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2012/052128 WO2013030577A1 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
Country Status (22)
Country | Link |
---|---|
US (2) | US10900064B2 (en) |
EP (2) | EP3483608B1 (en) |
JP (1) | JP6322845B2 (en) |
KR (1) | KR102074528B1 (en) |
CN (1) | CN104067124B (en) |
AU (1) | AU2012300641B2 (en) |
BR (1) | BR112014005087B1 (en) |
CA (1) | CA2845993C (en) |
DK (1) | DK2751568T3 (en) |
ES (1) | ES2717659T3 (en) |
GB (1) | GB201115095D0 (en) |
HK (1) | HK1199760A1 (en) |
HR (1) | HRP20190533T1 (en) |
HU (1) | HUE043386T2 (en) |
MX (1) | MX364410B (en) |
PL (1) | PL2751568T3 (en) |
PT (1) | PT2751568T (en) |
RU (2) | RU2687483C2 (en) |
SG (2) | SG10201601153RA (en) |
TR (1) | TR201904386T4 (en) |
WO (1) | WO2013030577A1 (en) |
ZA (1) | ZA201401295B (en) |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2775304A1 (en) * | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
WO2015048535A1 (en) * | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
WO2017001863A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in sputum samples |
WO2017001864A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in fecal samples |
WO2017068359A1 (en) * | 2015-10-21 | 2017-04-27 | Belgian Volition Sprl | Method for detecting nucleosomes containing histone modifications and variants |
US9639657B2 (en) | 2008-08-04 | 2017-05-02 | Natera, Inc. | Methods for allele calling and ploidy calling |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US10017812B2 (en) | 2010-05-18 | 2018-07-10 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10061890B2 (en) | 2009-09-30 | 2018-08-28 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10113196B2 (en) | 2010-05-18 | 2018-10-30 | Natera, Inc. | Prenatal paternity testing using maternal blood, free floating fetal DNA and SNP genotyping |
GB201818965D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Method for the detection of colorectal cancer |
GB201818963D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Methof for the detection of prostate cancer |
US10179937B2 (en) | 2014-04-21 | 2019-01-15 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
GB201906201D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Voltion Sprl | Method for the detection of protate cancer |
GB201906199D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
GB201912251D0 (en) | 2019-08-27 | 2019-10-09 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
US10526658B2 (en) | 2010-05-18 | 2020-01-07 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
EP3213084B1 (en) | 2014-10-29 | 2020-11-25 | Belgian Volition SPRL | Method for the enrichment of circulating tumor dna |
US10894976B2 (en) | 2017-02-21 | 2021-01-19 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
US10900064B2 (en) | 2011-09-01 | 2021-01-26 | Belgian Volition Sprl | Method for detecting nucleosomes containing nucleotides |
WO2021038010A1 (en) | 2019-08-27 | 2021-03-04 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
EP3798634A1 (en) | 2015-10-21 | 2021-03-31 | Belgian Volition SPRL | Method for the enrichment of cell free nucleosomes |
WO2021110776A1 (en) | 2019-12-02 | 2021-06-10 | Belgian Volition Sprl | Use of cell free nucleosomes as biomarkers |
GB202108185D0 (en) | 2021-06-08 | 2021-07-21 | Belgian Volition Sprl | Standardisation of nucleosome assays using biologically derived calibrants |
GB202108452D0 (en) | 2021-06-14 | 2021-07-28 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
WO2021186037A1 (en) | 2020-03-20 | 2021-09-23 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
US11306357B2 (en) | 2010-05-18 | 2022-04-19 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
WO2022112388A1 (en) | 2020-11-25 | 2022-06-02 | Belgian Volition Srl | Method for measurement of cell free nucleoprotein chromatin fragments |
WO2022144408A1 (en) | 2020-12-29 | 2022-07-07 | Belgian Volition Srl | Transcription factor binding site analysis of nucleosome depleted circulating cell free chromatin fragments |
WO2022144407A1 (en) | 2020-12-29 | 2022-07-07 | Belgian Volition Srl | Circulating transcription factor analysis |
WO2022152786A1 (en) | 2021-01-13 | 2022-07-21 | Belgian Volition Srl | Method for the detection of lung cancer |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
WO2023073179A1 (en) | 2021-10-29 | 2023-05-04 | Belgian Volition Srl | Homogeneous immunoassay method |
WO2023105062A1 (en) | 2021-12-09 | 2023-06-15 | Belgian Volition Srl | Method for the detection of blood cancer |
WO2023170298A1 (en) | 2022-03-11 | 2023-09-14 | Belgian Volition Srl | Differential diagnosis method |
WO2023194534A1 (en) | 2022-04-08 | 2023-10-12 | Belgian Volition Srl | Method for transplant organ health assessment |
WO2024042210A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
WO2024133222A1 (en) | 2022-12-19 | 2024-06-27 | Belgian Volition Srl | Assessment of biological samples for nucleic acid analysis |
US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107002021B (en) * | 2014-09-30 | 2021-12-03 | 深圳华大基因科技有限公司 | Biomarker for rheumatoid arthritis and application thereof |
EP3256858B1 (en) * | 2015-02-10 | 2020-03-25 | B.R.A.H.M.S GmbH | Histone h4 peptide as a biomarker |
EP3298169A4 (en) | 2015-05-18 | 2018-10-24 | Karius Inc. | Compositions and methods for enriching populations of nucleic acids |
GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
CN107858416B (en) * | 2016-09-19 | 2021-05-28 | 深圳华大生命科学研究院 | Biomarker combination for detecting endometriosis and application thereof |
CN107164508A (en) * | 2017-06-16 | 2017-09-15 | 上海易毕恩基因科技有限公司 | Gene marker for detecting liver cancer and application thereof |
CN107385051A (en) * | 2017-08-04 | 2017-11-24 | 上海易毕恩生物技术有限公司 | For detecting liver tumour good pernicious gene marker, kit and detection method |
ES2960550T3 (en) * | 2018-03-01 | 2024-03-05 | Epicypher Inc | Quantification of nucleosome modifications using chemically defined recombinant nucleosomes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999047924A1 (en) * | 1998-03-18 | 1999-09-23 | Roche Diagnostics Gmbh | Detection of apoptotic products |
WO2005019826A1 (en) | 2003-08-18 | 2005-03-03 | Chroma Therapeutics Limited | Detection of histone modification in cell-free nucleosomes |
WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
WO2008130516A1 (en) * | 2007-04-11 | 2008-10-30 | Manel Esteller | Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2652901A1 (en) | 1989-10-11 | 1991-04-12 | Pasteur Institut | Biological complexes based on nucleosomes, and their applications, especially in the field of in vitro diagnosis of lupus erythematosus disseminatus (LED) |
US6630301B1 (en) * | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
WO1997035589A1 (en) * | 1996-03-26 | 1997-10-02 | Kopreski Michael S | Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer |
NL1014106C2 (en) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Method for detecting a pathological abnormality in a cell, an antibody and an assay kit. |
DE602004018776D1 (en) | 2003-07-04 | 2009-02-12 | Johnson & Johnson Res Pty Ltd | METHOD FOR DETECTING ALKYLATED CYTOSINE IN DNA |
ATE554184T1 (en) * | 2004-12-16 | 2012-05-15 | Harvard College | HISTONE DEMETHYLATION MEDIATED BY THE NUCLEAR AMINO OXIDASE HOMOLOGUE LSD1 |
DE102005034628B4 (en) | 2005-07-19 | 2007-08-23 | Epigenomics Ag | Method for the investigation of cytosine methylations in DNA |
WO2007049286A1 (en) * | 2005-10-27 | 2007-05-03 | Tata Memorial Centre | A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma |
WO2007050706A2 (en) | 2005-10-27 | 2007-05-03 | University Of Missouri-Columbia | Dna methylation biomarkers in lymphoid and hematopoietic malignancies |
US20080311122A1 (en) | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
DE102006035600B3 (en) | 2006-07-27 | 2007-11-08 | Epigenomics Ag | Methylation detection, for diagnosis/prognosis of e.g. cancer disease, comprises converting non-methylated cytosine to uracil (nucleic acid) or into other base, so 5-methylcytosine remains unchanged and catalyzing nucleic acid activity |
US20080131954A1 (en) * | 2006-11-30 | 2008-06-05 | Canon U.S. Life Sciences, Inc. | Method of Separating Target DNA from Mixed DNA |
US7608402B2 (en) * | 2008-01-10 | 2009-10-27 | Weiwei Li | DNA methylation specific signal amplification |
WO2009115313A1 (en) | 2008-03-19 | 2009-09-24 | Oryzon Genomics, S.A. | Method and composition for methylation analysis |
RU2017138373A (en) | 2008-11-21 | 2019-02-11 | Юнивёрсити Оф Копенгаген | PRIMING AN IMMUNE RESPONSE |
US20120094949A1 (en) | 2009-04-14 | 2012-04-19 | The Regents Of The University Of California | Histone modification patterns for clinical diagnosis and prognosis of cancer |
CN102612652B (en) | 2009-08-06 | 2016-05-04 | 康奈尔大学 | For equipment and the method for analysis of molecules |
US20130183662A1 (en) | 2010-04-22 | 2013-07-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
US20130078642A1 (en) | 2010-06-03 | 2013-03-28 | Porto Conte Richerche S.R.L. | Biomarkers for lung neuroendocrine tumors |
FI20105715A0 (en) | 2010-06-18 | 2010-06-18 | Helsingin Yliopisto | A polyclonal antibody that binds to acetylated HMGB1 |
CN101955998A (en) * | 2010-07-20 | 2011-01-26 | 赵英仁 | Method for detecting necrosis degree of hepatic cells through level of plasma free DNA |
GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
BR112014013082B1 (en) * | 2011-12-07 | 2021-02-02 | Singapore Volition Pte Limited | use of a nucleosome-protein adduct and methods to detect the presence of a nucleosome-protein adduct |
EP3757210B1 (en) | 2012-03-02 | 2022-08-24 | Sequenom, Inc. | Methods for enriching cancer nucleic acid from a biological sample |
GB201303575D0 (en) | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for detecting histone modifications in nucleosomes |
-
2011
- 2011-09-01 GB GBGB1115095.0A patent/GB201115095D0/en not_active Ceased
-
2012
- 2012-08-31 BR BR112014005087-2A patent/BR112014005087B1/en not_active IP Right Cessation
- 2012-08-31 CA CA2845993A patent/CA2845993C/en active Active
- 2012-08-31 PT PT12756549T patent/PT2751568T/en unknown
- 2012-08-31 WO PCT/GB2012/052128 patent/WO2013030577A1/en active Application Filing
- 2012-08-31 AU AU2012300641A patent/AU2012300641B2/en active Active
- 2012-08-31 HU HUE12756549A patent/HUE043386T2/en unknown
- 2012-08-31 ES ES12756549T patent/ES2717659T3/en active Active
- 2012-08-31 SG SG10201601153RA patent/SG10201601153RA/en unknown
- 2012-08-31 RU RU2017126701A patent/RU2687483C2/en active
- 2012-08-31 CN CN201280053555.1A patent/CN104067124B/en active Active
- 2012-08-31 DK DK12756549.7T patent/DK2751568T3/en active
- 2012-08-31 EP EP18212025.3A patent/EP3483608B1/en active Active
- 2012-08-31 TR TR2019/04386T patent/TR201904386T4/en unknown
- 2012-08-31 JP JP2014527737A patent/JP6322845B2/en active Active
- 2012-08-31 PL PL12756549T patent/PL2751568T3/en unknown
- 2012-08-31 EP EP12756549.7A patent/EP2751568B1/en active Active
- 2012-08-31 SG SG11201400270PA patent/SG11201400270PA/en unknown
- 2012-08-31 KR KR1020147008108A patent/KR102074528B1/en active IP Right Grant
- 2012-08-31 RU RU2014112350/15A patent/RU2014112350A/en unknown
- 2012-08-31 US US14/239,783 patent/US10900064B2/en active Active
- 2012-08-31 MX MX2014002443A patent/MX364410B/en active IP Right Grant
-
2014
- 2014-02-20 ZA ZA2014/01295A patent/ZA201401295B/en unknown
-
2015
- 2015-01-08 HK HK15100175.0A patent/HK1199760A1/en not_active IP Right Cessation
-
2019
- 2019-03-19 HR HRP20190533TT patent/HRP20190533T1/en unknown
-
2020
- 2020-05-15 US US16/875,856 patent/US20200347435A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999047924A1 (en) * | 1998-03-18 | 1999-09-23 | Roche Diagnostics Gmbh | Detection of apoptotic products |
WO2005019826A1 (en) | 2003-08-18 | 2005-03-03 | Chroma Therapeutics Limited | Detection of histone modification in cell-free nucleosomes |
WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
WO2008130516A1 (en) * | 2007-04-11 | 2008-10-30 | Manel Esteller | Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer |
Non-Patent Citations (34)
Title |
---|
"Methylamp TM Global DNA Methylation Quantification Kit, User Guide", 2009, EPIGENTEK GROUP INC |
"Product Manual for", 2011, CELL BIOLABS, INC., article "Global DNA Methylation ELISA Kit (5'-methyl-2'-deoxycytidine Quantitation" |
ALLEN ET AL.: "A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements", NUCLEIC ACIDS RESEARCH, vol. 32, no. 3, XP002422114 |
BOULARD ET AL.: "Histone variant macroH2A1 deletion in mice causes female-specific steatosis", EPIGENETICS & CHROMATIN, vol. 3, no. 8, 2010, pages 1 - 13 |
DAI; ELISA ET AL.: "Detection of Post-translational Modifications on Native Intact Nucleosomes", J VIS EXP., vol. 50, 2011, Retrieved from the Internet <URL:http://www.jove.com/details.php?id=2593 doi: 10.3791/2593> |
DELIGEZER ET AL.: "Sequence-Specific Histone Methylation Is Detectable on Circulating Nucleosomes in Plasma", CLINICAL CHEMISTRY, vol. 54, no. 7, 2008, pages 1125 - 1131, XP055334679, DOI: doi:10.1373/clinchem.2007.101766 |
ESTELLER: "Cancer epigenomics: DNA methylomes and histone-modification maps", NATURE REVIEWS GENETICS, vol. 8, 2007, pages 286 - 298 |
FEINBERG; VOGELSTEIN: "Hypomethylation distinguishes genes of some human cancers from their normal counterparts", NATURE, vol. 301, 1983, pages 89 - 92, XP001154390, DOI: doi:10.1038/301089a0 |
GRUTZMANN ET AL.: "Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay", PLOS ONE, vol. 3, no. 11, pages E3759 |
HERRANZ; ESTELLER: "DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets", METHODS MOL BIO, vol. L.361, 2007, pages 25 - 62, XP009115201 |
HERVOUET ET AL.: "Disruption of Dnmt1/PCNA/UHRF1 Interactions Promotes Tumorigenesis from Human and Mice Glial Cells", PLOS ONE, vol. 5, no. 6, 2010, pages E11333 |
HOLDENREIDER; STIEBER: "Clinical use of circulating nucleosomes", CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, vol. 46, no. 1, 2009, pages 1 - 24, XP008158588, DOI: doi:1O.IOBO/lOoW8360B02485B75 |
HOLDENRIEDER ET AL.: "Cell-Free DNA in Serum and Plasma: Comparison ofELISA and Quantitative PCR", CLINICAL CHEMISTRY, vol. 51, no. 8, 2005, pages 1544 - 1546, XP055333788, DOI: doi:10.1373/clinchem.2005.049320 |
HOLDENRIEDER ET AL.: "Nucleosomes in Serum as a Marker for Cell Death", CLIN CHEM LAB MED, vol. 39, no. 7, 2001, pages 596 - 605, XP008069587, DOI: doi:10.1515/CCLM.2001.095 |
HOLDENRIEDER ET AL.: "Nucleosomes in serum of patients with benign and malignant diseases", INT. J. CANCER (PRED. ONCOL., vol. 95, 2001, pages 114 - 120, XP002401433, DOI: doi:10.1002/1097-0215(20010320)95:2<114::AID-IJC1020>3.0.CO;2-Q |
HUA ET AL.: "Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression", MOLECULAR SYSTEMS BIOLOGY, vol. 4, 2008, XP009143575, DOI: doi:10.1038/MSB.2008.25 |
KAPOOR ET AL.: "The histone variant macroH2A suppresses melanoma progression through regulation of CDK8", NATURE, vol. 468, 2010, pages 1105 - 1111 |
MANSOUR ET AL.: "The Prognostic Significance of Whole Blood Global and Specific DNA Methylation Levels in Gastric Adenocarcinoma", PLOS ONE, vol. 5, no. 12, pages E15585 |
MARINO-RAMFREZ, L.; LEVINE, K.M.; MORALES, M.; ZHANG, S.; MORELAND, R.T.; BAXEVANIS, A.D.; LANDSMAN, D., THE HISTONE DATABASE: AN INTEGRATED RESOURCE FOR HISTONES AND HISTONE FOLD-CONTAINING PROTEINS, vol. 2011, Retrieved from the Internet <URL:http://genome.nhgri.nih.gov/histones/complete.shtml> |
MOORE ET AL.: "Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study", THE LANCET ONCOLOGY, vol. 9, no. 4, 2008, pages 359 - 366, XP022593855, DOI: doi:10.1016/S1470-2045(08)70038-X |
NATURE MEDICINE, vol. 17, no. 3, 2011, pages 330 - 339 |
OGOSHI ET AL.: "Genomics", 2011, IN PRESS, article "Genome-wide profiling of DNA methylation in human cancer cells" |
ONCOGENE, vol. 28, no. 38, 2009, pages 3423 - 8 |
PENNINGS ET AL.: "DNA methylation, nucleosome formation and positioning", BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 3, no. 4, 2005, pages 351 - 361 |
SALGAME ET AL.: "An ELISA for detection of apoptosis", NUCLEIC ACIDS RESEARCH, vol. 25, no. 3, 1997, pages 680 - 681, XP055046512, DOI: doi:10.1093/nar/25.3.680 |
STROUD ET AL.: "5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells", GENOME BIOLOGY, vol. 12, 2011, pages R54, XP021106544, DOI: doi:10.1186/gb-2011-12-6-r54 |
SUZANNE H PARKER ET AL: "The roles of translation initiation regulation in ultraviolet light-induced apoptosis", MOLECULAR AND CELLULAR BIOCHEMISTRY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 293, no. 1-2, 20 June 2006 (2006-06-20), pages 173 - 181, XP019452576, ISSN: 1573-4919, DOI: 10.1007/S11010-006-9239-Y * |
TACHIWANA ET AL.: "Structures of human nucleosomes containing major histone H3 variants", ACTA CRYST, vol. D67, 2011, pages 578 - 583 |
TING HSIUNG ET AL.: "Global DNA Methylation Level in Whole Blood as a Biomarker in Head and Neck Squamous Cell Carcinoma", CANCER EPIDEMIOLOGY,BIOMARKERS & PREVENTION, vol. 16, no. 1, 2007, pages 108 - 114 |
VAN NIEUWENHUIJZE ET AL.: "Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for sysytemic lupus erythematosus", ANN RHEUM DIS, vol. 62, 2003, pages 10 - 14, XP055336175, DOI: doi:10.1136/ard.62.1.10 |
VASSER ET AL.: "Measurement of Global DNA Methylation", GENETIC ENGINEERING AND BIOTECHNOLOGY NEWS, vol. 29, no. 7, 2009 |
WHITTLE ET AL.: "The Genomic Distribution and Function of Histone Variant HTZ-1 during C. elegans Embryogenesis", PLOS GENET, vol. 4, no. 9, 2008, pages 1 - 17 |
ZEE ET AL.: "Global turnover of histone post-translational modifications and variants in human cells", EPIGENETICS & CHROMATIN, vol. 3, no. 22, 2010, pages 1 - 11 |
ZHANG ET AL.: "Analysis of global DNA methylation by hydrophilic interaction ultra highpressure liquid chromatography tandem mass spectrometry", ANALYTICAL BIOCHEMISTRY, vol. 413, no. 2, 2011, pages 164 - 170, XP028195957, DOI: doi:10.1016/j.ab.2011.01.029 |
Cited By (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10392664B2 (en) | 2005-07-29 | 2019-08-27 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10266893B2 (en) | 2005-07-29 | 2019-04-23 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10260096B2 (en) | 2005-07-29 | 2019-04-16 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10227652B2 (en) | 2005-07-29 | 2019-03-12 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11306359B2 (en) | 2005-11-26 | 2022-04-19 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US10711309B2 (en) | 2005-11-26 | 2020-07-14 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US9695477B2 (en) | 2005-11-26 | 2017-07-04 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US10597724B2 (en) | 2005-11-26 | 2020-03-24 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US9430611B2 (en) | 2005-11-26 | 2016-08-30 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US10240202B2 (en) | 2005-11-26 | 2019-03-26 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US9639657B2 (en) | 2008-08-04 | 2017-05-02 | Natera, Inc. | Methods for allele calling and ploidy calling |
US10216896B2 (en) | 2009-09-30 | 2019-02-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10522242B2 (en) | 2009-09-30 | 2019-12-31 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10061890B2 (en) | 2009-09-30 | 2018-08-28 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10061889B2 (en) | 2009-09-30 | 2018-08-28 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10113196B2 (en) | 2010-05-18 | 2018-10-30 | Natera, Inc. | Prenatal paternity testing using maternal blood, free floating fetal DNA and SNP genotyping |
US11746376B2 (en) | 2010-05-18 | 2023-09-05 | Natera, Inc. | Methods for amplification of cell-free DNA using ligated adaptors and universal and inner target-specific primers for multiplexed nested PCR |
US11306357B2 (en) | 2010-05-18 | 2022-04-19 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11286530B2 (en) | 2010-05-18 | 2022-03-29 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10174369B2 (en) | 2010-05-18 | 2019-01-08 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11111545B2 (en) | 2010-05-18 | 2021-09-07 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11482300B2 (en) | 2010-05-18 | 2022-10-25 | Natera, Inc. | Methods for preparing a DNA fraction from a biological sample for analyzing genotypes of cell-free DNA |
US10793912B2 (en) | 2010-05-18 | 2020-10-06 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US12020778B2 (en) | 2010-05-18 | 2024-06-25 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10017812B2 (en) | 2010-05-18 | 2018-07-10 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10526658B2 (en) | 2010-05-18 | 2020-01-07 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11519035B2 (en) | 2010-05-18 | 2022-12-06 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10538814B2 (en) | 2010-05-18 | 2020-01-21 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10557172B2 (en) | 2010-05-18 | 2020-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11525162B2 (en) | 2010-05-18 | 2022-12-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US10590482B2 (en) | 2010-05-18 | 2020-03-17 | Natera, Inc. | Amplification of cell-free DNA using nested PCR |
US10774380B2 (en) | 2010-05-18 | 2020-09-15 | Natera, Inc. | Methods for multiplex PCR amplification of target loci in a nucleic acid sample |
US10597723B2 (en) | 2010-05-18 | 2020-03-24 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10731220B2 (en) | 2010-05-18 | 2020-08-04 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11312996B2 (en) | 2010-05-18 | 2022-04-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10655180B2 (en) | 2010-05-18 | 2020-05-19 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10900064B2 (en) | 2011-09-01 | 2021-01-26 | Belgian Volition Sprl | Method for detecting nucleosomes containing nucleotides |
EP2775304A1 (en) * | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
WO2014135469A3 (en) * | 2013-03-07 | 2014-10-30 | Universitatsspital Basel | Methods for detecting inflammatory disorders |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
WO2015048535A1 (en) * | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
US9499870B2 (en) * | 2013-09-27 | 2016-11-22 | Natera, Inc. | Cell free DNA diagnostic testing standards |
US20150147815A1 (en) * | 2013-09-27 | 2015-05-28 | Natera, Inc. | Cell free dna diagnostic testing standards |
US11371100B2 (en) | 2014-04-21 | 2022-06-28 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11408037B2 (en) | 2014-04-21 | 2022-08-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US10597709B2 (en) | 2014-04-21 | 2020-03-24 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11414709B2 (en) | 2014-04-21 | 2022-08-16 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11390916B2 (en) | 2014-04-21 | 2022-07-19 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11530454B2 (en) | 2014-04-21 | 2022-12-20 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US10597708B2 (en) | 2014-04-21 | 2020-03-24 | Natera, Inc. | Methods for simultaneous amplifications of target loci |
US11486008B2 (en) | 2014-04-21 | 2022-11-01 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US10351906B2 (en) | 2014-04-21 | 2019-07-16 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11319595B2 (en) | 2014-04-21 | 2022-05-03 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
US11319596B2 (en) | 2014-04-21 | 2022-05-03 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US10179937B2 (en) | 2014-04-21 | 2019-01-15 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
EP3809140A1 (en) | 2014-10-29 | 2021-04-21 | Belgian Volition SPRL | Method for the enrichment of circulating tumor dna |
EP3213084B2 (en) † | 2014-10-29 | 2023-12-13 | Belgian Volition SPRL | Method for the enrichment of circulating tumor dna |
EP3213084B1 (en) | 2014-10-29 | 2020-11-25 | Belgian Volition SPRL | Method for the enrichment of circulating tumor dna |
US11946101B2 (en) | 2015-05-11 | 2024-04-02 | Natera, Inc. | Methods and compositions for determining ploidy |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
WO2017001863A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in sputum samples |
WO2017001864A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in fecal samples |
WO2017068359A1 (en) * | 2015-10-21 | 2017-04-27 | Belgian Volition Sprl | Method for detecting nucleosomes containing histone modifications and variants |
US10768182B2 (en) | 2015-10-21 | 2020-09-08 | Belgian Volition Sprl | Method for detecting nucleosomes containing histone modifications and variants |
EP3798634A1 (en) | 2015-10-21 | 2021-03-31 | Belgian Volition SPRL | Method for the enrichment of cell free nucleosomes |
US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US10533219B2 (en) | 2016-12-07 | 2020-01-14 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US11519028B2 (en) | 2016-12-07 | 2022-12-06 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US10577650B2 (en) | 2016-12-07 | 2020-03-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US11530442B2 (en) | 2016-12-07 | 2022-12-20 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US10894976B2 (en) | 2017-02-21 | 2021-01-19 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
GB201818963D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Methof for the detection of prostate cancer |
GB201818965D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Method for the detection of colorectal cancer |
WO2020221921A1 (en) | 2019-05-02 | 2020-11-05 | Belgian Volition Sprl | Method for the detection of cancer |
WO2020221922A1 (en) | 2019-05-02 | 2020-11-05 | Belgian Volition Sprl | Method for the detection of prostate cancer |
GB201906199D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
GB201906201D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Voltion Sprl | Method for the detection of protate cancer |
WO2021038010A1 (en) | 2019-08-27 | 2021-03-04 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
GB201912251D0 (en) | 2019-08-27 | 2019-10-09 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
WO2021110776A1 (en) | 2019-12-02 | 2021-06-10 | Belgian Volition Sprl | Use of cell free nucleosomes as biomarkers |
WO2021186037A1 (en) | 2020-03-20 | 2021-09-23 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
EP4239077A2 (en) | 2020-03-20 | 2023-09-06 | Belgian Volition SRL | Triaging method using cell free nucleosome levels |
WO2022112388A1 (en) | 2020-11-25 | 2022-06-02 | Belgian Volition Srl | Method for measurement of cell free nucleoprotein chromatin fragments |
WO2022144408A1 (en) | 2020-12-29 | 2022-07-07 | Belgian Volition Srl | Transcription factor binding site analysis of nucleosome depleted circulating cell free chromatin fragments |
WO2022144407A1 (en) | 2020-12-29 | 2022-07-07 | Belgian Volition Srl | Circulating transcription factor analysis |
WO2022152786A1 (en) | 2021-01-13 | 2022-07-21 | Belgian Volition Srl | Method for the detection of lung cancer |
GB202108185D0 (en) | 2021-06-08 | 2021-07-21 | Belgian Volition Sprl | Standardisation of nucleosome assays using biologically derived calibrants |
WO2022258690A1 (en) | 2021-06-08 | 2022-12-15 | Belgian Volition Srl | Standardisation of nucleosome assays using biologically derived calibrants |
GB202108452D0 (en) | 2021-06-14 | 2021-07-28 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
WO2023073179A1 (en) | 2021-10-29 | 2023-05-04 | Belgian Volition Srl | Homogeneous immunoassay method |
WO2023105062A1 (en) | 2021-12-09 | 2023-06-15 | Belgian Volition Srl | Method for the detection of blood cancer |
WO2023170298A1 (en) | 2022-03-11 | 2023-09-14 | Belgian Volition Srl | Differential diagnosis method |
WO2023194534A1 (en) | 2022-04-08 | 2023-10-12 | Belgian Volition Srl | Method for transplant organ health assessment |
WO2024042210A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
WO2024133222A1 (en) | 2022-12-19 | 2024-06-27 | Belgian Volition Srl | Assessment of biological samples for nucleic acid analysis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200347435A1 (en) | Method for detecting nucleosomes containing nucleotides | |
US20230116530A1 (en) | Method for detecting nucleosomes containing histone variants | |
US9222937B2 (en) | Method for detecting nucleosomes | |
US20170003296A1 (en) | Method for detecting histone modifications in nucleosomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12756549 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2845993 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014527737 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/002443 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012300641 Country of ref document: AU Date of ref document: 20120831 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147008108 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14239783 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014112350 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005087 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005087 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140305 |